• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119).

作者信息

Beyer-Westendorf Jan, Marten Sandra, Naue Christiane, Tittl Luise, Sockel Katja, Middecke Jan Moritz, Bornhäuser Martin

机构信息

Department of Medicine I, Division of Hematology, Hemostaseology and Coagulation, University Hospital "Carl Gustav Carus" Dresden, Technical University, Fetscherstrasse 74, D-01307 Dresden, Germany; Kings Thrombosis Service, Department of Hematology, Kings College London, UK.

Department of Medicine I, Division of Hematology, Hemostaseology and Coagulation, University Hospital "Carl Gustav Carus" Dresden, Technical University, Fetscherstrasse 74, D-01307 Dresden, Germany.

出版信息

Thromb Res. 2020 Jul;191:50-55. doi: 10.1016/j.thromres.2020.04.030. Epub 2020 Apr 25.

DOI:10.1016/j.thromres.2020.04.030
PMID:32387685
Abstract
摘要

相似文献

1
Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119).
Thromb Res. 2020 Jul;191:50-55. doi: 10.1016/j.thromres.2020.04.030. Epub 2020 Apr 25.
2
Clinical effectiveness and safety of edoxaban in obese patients - Results of the prospective Dresden NOAC Registry (NCT01588119).依度沙班在肥胖患者中的临床有效性和安全性——德累斯顿新型口服抗凝药前瞻性注册研究（NCT01588119）结果
Thromb Res. 2023 Aug;228:134-136. doi: 10.1016/j.thromres.2023.05.026. Epub 2023 Jun 2.
3
DTI/DXI interferences with global coagulation tests in emergency hospital admissions - Results of the prospective Dresden NOAC Registry (NCT01588119).DTI/DXI 对急诊入院患者的整体凝血检测的干扰 - 前瞻性德累斯顿新型口服抗凝剂注册研究（NCT01588119）的结果。
Thromb Res. 2019 Oct;182:101-109. doi: 10.1016/j.thromres.2019.08.020. Epub 2019 Aug 22.
4
Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.直接口服抗Xa因子抑制剂治疗的育龄期女性阴道出血和月经过多的管理及结局：病例系列
Lancet Haematol. 2016 Oct;3(10):e480-e488. doi: 10.1016/S2352-3026(16)30111-9.
5
Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.凝血因子Xa抑制剂：用于治疗非瓣膜性心房颤动的新型治疗类别。
Ther Adv Cardiovasc Dis. 2016 Feb;10(1):37-49. doi: 10.1177/1753944715605011. Epub 2015 Sep 16.
6
Factor Xa inhibitors: critical considerations for clinical development and testing.Xa 因子抑制剂：临床开发和检测的关键考虑因素。
J Thromb Thrombolysis. 2021 Aug;52(2):397-402. doi: 10.1007/s11239-021-02455-x. Epub 2021 May 15.
7
Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?Xa 因子的非止血活性：抗 Xa 直接口服抗凝剂是否具有多效性作用？
Angiology. 2019 Nov;70(10):896-907. doi: 10.1177/0003319719840861. Epub 2019 Apr 22.
8
"": Anticoagulation Management in Patients with Atrial Fibrillation and Prosthetic Valves in the Era of Direct Oral Anticoagulants.“”：直接口服抗凝剂时代的心房颤动和人工瓣膜患者的抗凝管理。
Medicina (Kaunas). 2019 Aug 4;55(8):437. doi: 10.3390/medicina55080437.
9
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.21105例心房颤动患者随机接受依度沙班或华法林治疗后的全身性、非脑性动脉栓塞：心房颤动-心肌梗死溶栓研究48试验中下一代Xa因子有效抗凝治疗的结果
Am Heart J. 2015 Oct;170(4):669-74. doi: 10.1016/j.ahj.2015.06.020. Epub 2015 Jul 2.
10
[Large studies of NOAC shows good and safe stroke protection].[关于新型口服抗凝药的大型研究显示其对中风有良好且安全的预防作用]
Lakartidningen. 2015 Sep 8;112:DIPE.